Reducing the burden of Sickle Cell Disease (SCD) requires substantial financial and political commitment to improving data-collection, diagnosis, treatment and training – doing so will positively impact the lives of millions of patients and families worldwide – says a new Commission published in The Lancet Haematology journal.
Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success – Pharmaceutical Technology
According to GlobalData, Novo Nordisk’s Wegovy (semaglutide) (indicated for obesity) and Ozempic are forecast to reach sales of $8.1bn and $2.1bn by 2031, respectively. Credit:
October 17, 2023